Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine (EDIT) Form 144 notice reports a proposed sale of 7,000 shares of Common Stock to be executed through ETrade on 09/03/2025 on Nasdaq with an aggregate market value of $19,110.00. The filing shows these shares were acquired on 09/02/2025 through restricted stock unit vesting (equity compensation), with 11,294 shares listed as acquired on that date. The filing also discloses a sale by Gilmore O'Neill of 15,192 shares on 06/03/2025 for gross proceeds of $26,195.57. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Editas Medicine (EDIT) submitted a Form 144 disclosing a proposed sale of 800 shares of common stock with an aggregate market value of $2,184, listed for sale on Nasdaq and dated approximately 09/03/2025. The securities were acquired on 09/02/2025 through restricted stock unit vesting (1,550 shares acquired) and payment was in the form of equity compensation. The filing also reports two prior sales by the same person in the past three months: 726 shares on 06/03/2025 ($1,251.84) and 5,121 shares on 07/31/2025 ($12,756.92). The form includes the standard attestation that the seller is unaware of undisclosed material adverse information.
Editas Medicine (EDIT) reported a net loss of $129.3 million for the six months ended June 30, 2025, or $1.54 per share, widening its accumulated deficit to $1.6 billion. Total assets fell to $210.6 million from $341.6 million at year-end 2024, and stockholders' equity declined to $19.2 million. Cash and cash equivalents were $138.5 million and marketable securities were $39.9 million, totaling $178.5 million in liquid investments.
The company discontinued its ex vivo reni-cel program and initiated a workforce reduction of approximately 180 positions (about 65%), recording $66.9 million of restructuring and impairment charges in the six months and $79.2 million since the December 2024 decision. Editas received $57.0 million from DRI under a sale-of-future-revenues agreement (accounted for as debt; estimated effective interest rate 15.1%, liability $56.7 million) and has an amended ATM facility with $141.4 million remaining capacity after $8.6 million of sales. Management expects existing cash, cash equivalents and marketable securities to fund operations for at least twelve months from the consolidated financial statement issuance date.
Editas Medicine announced that it has furnished a press release reporting its financial results for the fiscal quarter ended June 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is expressly furnished, not filed, so the numerical results and business detail are contained in that exhibit rather than in the body of the filing.
Editas Medicine insider transaction by SVP & Chief Financial Officer Amy Parison: The filing reports a non-discretionary sale of 679 shares of common stock at $2.58 per share, executed under a durable automatic sales instruction plan. The sale satisfied tax withholding obligations arising from the vesting of restricted stock units and is explicitly described as not a discretionary trade by the reporting person.
After the reported sale the reporting person beneficially owned 16,827 shares directly. The filing identifies the issuer as Editas Medicine, Inc. and classifies the report as a Form 4 statement of changes in beneficial ownership.